Assets
(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Angiotensin II type 1 receptor / L-type calcium channel / Na-Cl cotransporterSmall molecule | Hypertension | |
| Phase 1 | Undisclosed / early pipeline | Atherosclerotic Cardiovascular Disease | |
RosuvamibeNo recent activity | Preclinical / Unstaged | HMG-CoA reductase / NPC1L1Small molecule | Atherosclerotic Cardiovascular Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.